302 related articles for article (PubMed ID: 26784941)
21. A Contraction Stress Model of Hypertrophic Cardiomyopathy due to Sarcomere Mutations.
Cohn R; Thakar K; Lowe A; Ladha FA; Pettinato AM; Romano R; Meredith E; Chen YS; Atamanuk K; Huey BD; Hinson JT
Stem Cell Reports; 2019 Jan; 12(1):71-83. PubMed ID: 30554920
[TBL] [Abstract][Full Text] [Related]
22. Contractile abnormalities and altered drug response in engineered heart tissue from Mybpc3-targeted knock-in mice.
Stöhr A; Friedrich FW; Flenner F; Geertz B; Eder A; Schaaf S; Hirt MN; Uebeler J; Schlossarek S; Carrier L; Hansen A; Eschenhagen T
J Mol Cell Cardiol; 2013 Oct; 63():189-98. PubMed ID: 23896226
[TBL] [Abstract][Full Text] [Related]
23. Establishing a new human hypertrophic cardiomyopathy-specific model using human embryonic stem cells.
Cai H; Li B; Bai A; Huang J; Zhan Y; Sun N; Liang Q; Xu C
Exp Cell Res; 2020 Feb; 387(1):111736. PubMed ID: 31759053
[TBL] [Abstract][Full Text] [Related]
24. Investigating the cardiac pathology of SCO2-mediated hypertrophic cardiomyopathy using patients induced pluripotent stem cell-derived cardiomyocytes.
Hallas T; Eisen B; Shemer Y; Ben Jehuda R; Mekies LN; Naor S; Schick R; Eliyahu S; Reiter I; Vlodavsky E; Katz YS; Õunap K; Lorber A; Rodenburg R; Mandel H; Gherghiceanu M; Binah O
J Cell Mol Med; 2018 Feb; 22(2):913-925. PubMed ID: 29193756
[TBL] [Abstract][Full Text] [Related]
25. Functional and transcriptomic insights into pathogenesis of R9C phospholamban mutation using human induced pluripotent stem cell-derived cardiomyocytes.
Ceholski DK; Turnbull IC; Kong CW; Koplev S; Mayourian J; Gorski PA; Stillitano F; Skodras AA; Nonnenmacher M; Cohen N; Björkegren JLM; Stroik DR; Cornea RL; Thomas DD; Li RA; Costa KD; Hajjar RJ
J Mol Cell Cardiol; 2018 Jun; 119():147-154. PubMed ID: 29752948
[TBL] [Abstract][Full Text] [Related]
26. Hypertrophic cardiomyopathy β-cardiac myosin mutation (P710R) leads to hypercontractility by disrupting super relaxed state.
Vander Roest AS; Liu C; Morck MM; Kooiker KB; Jung G; Song D; Dawood A; Jhingran A; Pardon G; Ranjbarvaziri S; Fajardo G; Zhao M; Campbell KS; Pruitt BL; Spudich JA; Ruppel KM; Bernstein D
Proc Natl Acad Sci U S A; 2021 Jun; 118(24):. PubMed ID: 34117120
[TBL] [Abstract][Full Text] [Related]
27. Isogenic Pairs of hiPSC-CMs with Hypertrophic Cardiomyopathy/LVNC-Associated ACTC1 E99K Mutation Unveil Differential Functional Deficits.
Smith JGW; Owen T; Bhagwan JR; Mosqueira D; Scott E; Mannhardt I; Patel A; Barriales-Villa R; Monserrat L; Hansen A; Eschenhagen T; Harding SE; Marston S; Denning C
Stem Cell Reports; 2018 Nov; 11(5):1226-1243. PubMed ID: 30392975
[TBL] [Abstract][Full Text] [Related]
28. Maturing human pluripotent stem cell-derived cardiomyocytes in human engineered cardiac tissues.
Feric NT; Radisic M
Adv Drug Deliv Rev; 2016 Jan; 96():110-34. PubMed ID: 25956564
[TBL] [Abstract][Full Text] [Related]
29. Impact of ANKRD1 mutations associated with hypertrophic cardiomyopathy on contraction parameters of engineered heart tissue.
Crocini C; Arimura T; Reischmann S; Eder A; Braren I; Hansen A; Eschenhagen T; Kimura A; Carrier L
Basic Res Cardiol; 2013 May; 108(3):349. PubMed ID: 23572067
[TBL] [Abstract][Full Text] [Related]
30. Real-Time Force and Frequency Analysis of Engineered Human Heart Tissue Derived from Induced Pluripotent Stem Cells Using Magnetic Sensing.
Bielawski KS; Leonard A; Bhandari S; Murry CE; Sniadecki NJ
Tissue Eng Part C Methods; 2016 Oct; 22(10):932-940. PubMed ID: 27600722
[TBL] [Abstract][Full Text] [Related]
31. Diltiazem prevents stress-induced contractile deficits in cardiomyocytes, but does not reverse the cardiomyopathy phenotype in Mybpc3-knock-in mice.
Flenner F; Geertz B; Reischmann-Düsener S; Weinberger F; Eschenhagen T; Carrier L; Friedrich FW
J Physiol; 2017 Jun; 595(12):3987-3999. PubMed ID: 28090637
[TBL] [Abstract][Full Text] [Related]
32. Advances in Hypertrophic Cardiomyopathy Disease Modelling Using hiPSC-Derived Cardiomyocytes.
Dababneh S; Hamledari H; Maaref Y; Jayousi F; Hosseini DB; Khan A; Jannati S; Jabbari K; Arslanova A; Butt M; Roston TM; Sanatani S; Tibbits GF
Can J Cardiol; 2024 May; 40(5):766-776. PubMed ID: 37952715
[TBL] [Abstract][Full Text] [Related]
33. Applying Patient-Specific Induced Pluripotent Stem Cells to Create a Model of Hypertrophic Cardiomyopathy.
Dementyeva EV; Medvedev SP; Kovalenko VR; Vyatkin YV; Kretov EI; Slotvitsky MM; Shtokalo DN; Pokushalov EA; Zakian SM
Biochemistry (Mosc); 2019 Mar; 84(3):291-298. PubMed ID: 31221067
[TBL] [Abstract][Full Text] [Related]
34. Ranolazine Prevents Phenotype Development in a Mouse Model of Hypertrophic Cardiomyopathy.
Coppini R; Mazzoni L; Ferrantini C; Gentile F; Pioner JM; Laurino A; Santini L; Bargelli V; Rotellini M; Bartolucci G; Crocini C; Sacconi L; Tesi C; Belardinelli L; Tardiff J; Mugelli A; Olivotto I; Cerbai E; Poggesi C
Circ Heart Fail; 2017 Mar; 10(3):. PubMed ID: 28255011
[TBL] [Abstract][Full Text] [Related]
35. Serum supplemented culture medium masks hypertrophic phenotypes in human pluripotent stem cell derived cardiomyocytes.
Dambrot C; Braam SR; Tertoolen LG; Birket M; Atsma DE; Mummery CL
J Cell Mol Med; 2014 Aug; 18(8):1509-18. PubMed ID: 24981391
[TBL] [Abstract][Full Text] [Related]
36. Modeling hypertrophic cardiomyopathy with human cardiomyocytes derived from induced pluripotent stem cells.
Li J; Feng X; Wei X
Stem Cell Res Ther; 2022 Jun; 13(1):232. PubMed ID: 35659761
[TBL] [Abstract][Full Text] [Related]
37. Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy.
Cashman TJ; Josowitz R; Gelb BD; Li RA; Dubois NC; Costa KD
J Vis Exp; 2016 Mar; (109):e53447. PubMed ID: 26967678
[TBL] [Abstract][Full Text] [Related]
38. Finding the rhythm of sudden cardiac death: new opportunities using induced pluripotent stem cell-derived cardiomyocytes.
Sallam K; Li Y; Sager PT; Houser SR; Wu JC
Circ Res; 2015 Jun; 116(12):1989-2004. PubMed ID: 26044252
[TBL] [Abstract][Full Text] [Related]
39. Correlation between frataxin expression and contractility revealed by in vitro Friedreich's ataxia cardiac tissue models engineered from human pluripotent stem cells.
Wong AO; Wong G; Shen M; Chow MZ; Tse WW; Gurung B; Mak SY; Lieu DK; Costa KD; Chan CW; Martelli A; Nabhan JF; Li RA
Stem Cell Res Ther; 2019 Jul; 10(1):203. PubMed ID: 31286988
[TBL] [Abstract][Full Text] [Related]
40. Designing a Bioreactor to Improve Data Acquisition and Model Throughput of Engineered Cardiac Tissues.
van Neste CC; Wiley KA; Chang SW; Borrello J; Turnbull IC; Costa KD
J Vis Exp; 2023 Jun; (196):. PubMed ID: 37335101
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
